Irritable Bowel Syndrome Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Irritable Bowel Syndrome market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as GlaxoSmithKline, Ziauddin University, Geophyt S.r.l.s., Urovant Sciences GmbH, AbbVie, SOFAR S.p.A, Menarini Group, Tioga Pharmaceuticals, 4D pharma plc, Bristol-Myers Squibb, Pharmos, Ocera Therapeutics, SOFAR S.p.A., Bausch Health Americas, Inc., Furiex Pharmaceuticals, Inc, Alizyme, Mayo Clinic, Bayer, Abbott

[Nevada, United States] - DelveInsight's "Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Irritable Bowel Syndrome, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Irritable Bowel Syndrome Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Irritable Bowel Syndrome Market Report:
The Irritable Bowel Syndrome market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: CinPhloro Pharma, LLC announced that the goal of their clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients.
In September, 2024: Tasly Pharmaceutical Group Co., Ltd announced that the aim of their clinical trial is to evaluate the efficacy and safety of Changkang granule as compared to placebo over a 8-week treatment period and explore TCM syndrome types.
In August, 2024: AbbVie announced that the objective of their study is to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.
In June, 2024: Mayo Clinic announced that the aim of their study is to evaluate the efficacy of rimegepant on abdominal pain scores in participants with non-constipation IBS.
According to DelveInsight's analysis, which utilized both secondary and primary research, the prevalence rate in the United States and Europe is 67% for females and 33% for males. In Japan, the prevalence is slightly different, with 59% for females and 41% for males.
As per Breen-Lyles et al. (2023), the mean irritable bowel syndrome symptom severity score in Rome IV patients was significantly higher than in Rome III criteria.
As per Jean-Marc et al. (2023), the severity-specific prevalence of irritable bowel syndrome in France was 31.3% for the moderately severe form and 68.7% for the severe form.
Key Irritable Bowel Syndrome Companies are as follows: GlaxoSmithKline, Ziauddin University, Geophyt S.r.l.s., Urovant Sciences GmbH, AbbVie, SOFAR S.p.A, Menarini Group, Tioga Pharmaceuticals, 4D pharma plc, Bristol-Myers Squibb, Pharmos, Ocera Therapeutics, SOFAR S.p.A., Bausch Health Americas, Inc., Furiex Pharmaceuticals, Inc, Alizyme, Mayo Clinic, Bayer, Abbott
Key Irritable Bowel Syndrome Therapies are as follow: GW876008, talnetant, Saccharomyces cerevisiae, Proklama, Vibegron, Bifidobacterium infantis, Pancrelipase, Nitazoxanide Eluxadoline, Mesalazine, Ibodutant, Asimadoline, Blautix, BMS-562086, Dextofisopam, AST-120, mesalazine, crofelemer, Eluxadoline, Renzapride, Pregabalin, BAY98-7411, Itopride: Abbott
Launching multiple stage Irritable Bowel Syndrome pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Irritable Bowel Syndrome market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Irritable Bowel Syndrome Overview:
Irritable bowel syndrome (IBS) affects 5-10% of the global population and is marked by abdominal pain or discomfort, along with chronic or recurrent diarrhea, constipation, or both. The exact cause of IBS is unknown, but it involves a disturbance in the interaction between the gut, brain, and nervous system, leading to changes in bowel movements and sensation.

Irritable Bowel Syndrome Epidemiology Segmentation:
The Irritable Bowel Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Irritable Bowel Syndrome Total Prevalent Cases
Irritable Bowel Syndrome Total Treated Cases
Irritable Bowel Syndrome Total Diagnosed Cases
Irritable Bowel Syndrome Gender-specific Cases

For more information about Irritable Bowel Syndrome companies working in the treatment market, visit https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Irritable Bowel Syndrome Market Insights
Irritable bowel syndrome (IBS) is a complex disorder characterized by motility dysfunction, visceral hypersensitivity, and various contributing factors including genetics, diet, and immune activation. Its diagnosis and management pose significant challenges globally. IBS manifests in diverse forms, classified by predominant stool texture, and imposes a substantial burden on healthcare systems worldwide. In the United States alone, direct medical costs associated with IBS reach up to USD 10 billion annually, exacerbated by high healthcare resource utilization and regional disparities in testing and treatment approaches.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Irritable Bowel Syndrome Therapies and Key Companies:
GW876008, talnetant: GlaxoSmithKline
Saccharomyces cerevisiae: Ziauddin University
Proklama: Geophyt S.r.l.s.
Vibegron: Urovant Sciences GmbH
Bifidobacterium infantis, Pancrelipase, Nitazoxanide
Eluxadoline: AbbVie
Mesalazine: SOFAR S.p.A
Ibodutant: Menarini Group
Asimadoline: Tioga Pharmaceuticals
Blautix: 4D pharma plc
BMS-562086: Bristol-Myers Squibb
Dextofisopam: Pharmos
AST-120: Ocera Therapeutics
mesalazine: SOFAR S.p.A.
crofelemer: Bausch Health Americas, Inc.
Eluxadoline: Furiex Pharmaceuticals, Inc
Renzapride: Alizyme
Pregabalin: Mayo Clinic
BAY98-7411: Bayer
Itopride: Abbott

Irritable Bowel Syndrome Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Irritable Bowel Syndrome.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Irritable Bowel Syndrome Market Drivers:
Rising Prevalence
Improved Diagnostic Methods:
Growing Focus on Targeted Therapies
Awareness and Patient Education
Innovation in Probiotics and Natural Therapies

Irritable Bowel Syndrome Market Barriers:
Lack of Definitive Treatments
Adverse Effects of Medications
Stringent Regulatory Approvals
Limited Awareness in Developing Regions

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Irritable Bowel Syndrome Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Irritable Bowel Syndrome Companies: GlaxoSmithKline, Ziauddin University, Geophyt S.r.l.s., Urovant Sciences GmbH, AbbVie, SOFAR S.p.A, Menarini Group, Tioga Pharmaceuticals, 4D pharma plc, Bristol-Myers Squibb, Pharmos, Ocera Therapeutics, SOFAR S.p.A., Bausch Health Americas, Inc., Furiex Pharmaceuticals, Inc, Alizyme, Mayo Clinic, Bayer, Abbott
Key Irritable Bowel Syndrome Therapies: GW876008, talnetant, Saccharomyces cerevisiae, Proklama, Vibegron, Bifidobacterium infantis, Pancrelipase, Nitazoxanide Eluxadoline, Mesalazine, Ibodutant, Asimadoline, Blautix, BMS-562086, Dextofisopam, AST-120, mesalazine, crofelemer, Eluxadoline, Renzapride, Pregabalin, BAY98-7411, Itopride: Abbott
Irritable Bowel Syndrome Therapeutic Assessment: Current marketed and emerging therapies
Irritable Bowel Syndrome Market Dynamics: Irritable Bowel Syndrome Market drivers and Irritable Bowel Syndrome barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Irritable Bowel Syndrome Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Irritable Bowel Syndrome market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Irritable Bowel Syndrome Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary of Irritable Bowel Syndrome
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Patient Journey
9 Key Endpoints in Irritable Bowel Syndrome Clinical Trials
10 Emerging Therapies
11 Marketed Therapies
12 Irritable Bowel Syndrome: The 7MM Analysis
13 Market Access and Reimbursement
14 KOL Views
15 SWOT Analysis
16 Unmet Needs
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.